<DOC>
	<DOC>NCT02158273</DOC>
	<brief_summary>The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo.</brief_summary>
	<brief_title>Medication Development in Alcoholism: Investigating PPAR Agonists</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Male or female volunteers, 1865 years of age Meets DSMV criteria for Alcohol Use Disorder â‰¥ moderate severity and DSMIV criteria for current alcohol dependence Subjects will not be seeking treatment because the medication studies are not treatment trials Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session Negative BAC and a CIWA score of &lt; 9 at screening and time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures In acceptable health in the judgment of the study physician, on the basis of interview, medical history, physical exam, ECG, urine test and lab tests Females with childbearing potential must have a negative serum pregnancy test on the screening visit with a negative urine pregnancy test at randomization and agree to use an effective method of birth control for the study duration and two weeks thereafter. Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent Willingness to comply with the provisions of the protocol and take daily oral medication Subjects with a medical condition that contraindicates the administration of fenofibrate or that will increase potential risk as determined by the Study Physician. GGT more than 3 times the upper limit of normal Female subjects with childbearing potential who are pregnant, nursing, or refuse to use an effective method of birth control for the duration of the study and two weeks thereafter Meets DSMV criteria for a major Axis I disorder including mood or anxiety disorders or substance use disorders (e.g., cocaine, amphetamines, heroin, PCP) other than alcohol or nicotine Has a positive UDS at screening or Visit 3 (laboratory session) Treatment within the month prior to screening with an investigational drug, vaccine or drugs that may influence study outcomes, or drugs that may pose a safety risk as determined by the Study Physician. History of hypersensitivity to the study drugs or the ingredients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alcohol</keyword>
	<keyword>Relapse</keyword>
</DOC>